Posts tagged “Quintiles”

Updated October 3

Quintiles, IMS Health complete $17B merger; no word on any job cuts

Quintiles has a new name: Quintiles IMS Holdings Inc. after the multi-billion-dollar merger between the two life science companies was officially wrapped up Monday morning. Will there be layoffs? That's note clear right now.

Updated October 3

Premium Lock QuintilesIMS management scorecard: IMS 8, Quintiles 11 but ...

In the $17 billion "merger of equals" between Quintiles and IMS Health, the new QuintilesIMS management tilts to IMS at the highest of three levels but the old Quintiles nabs well over half of the next two executive suite tiers.

Tom Pike  Tom Pike

Updated September 20

Premium Lock LabCorp names former Quintiles exec to lead Covance

John Ratliff, who resigned as president of Quintiles for "personal reasons" in 2013, is taking over as CEO of Covance Drug Development, which is now owned by LabCorp.

John Ratliff John Ratliff

Updated August 29

Premium Lock Quintiles CEO to take vice chair role in Q-IMS Health merger

Tom Pike  IMS Health Holdings will own a majority of shares if and when a proposed merger with Quintiles wins regulatory approval. And that ownership is shown in the lineup of the proposed executive lineup for a new company as Quintiles CEO Tom Pike takes on a lesser role.

August 29

Premium Lock Quintiles' COO, 2 board members to leave as Q, IMS Health merge

Kevin Gordon The $17 billion merger between Quintiles and IMS Health means more than a new title and responsibilities for Quintiles CEO Tom Pike. One of Quntiles' top executives will leave along with two board members if the deal wins regulatory approval.

July 20

Premium Lock Number of biotechs likely to use a CRO increasing

Worldwide Clinical Trials A recent survey by Morrisville-baed Worldwide Clinical Trials revealed that 62 percent of respondents are more likely to engage a clinical research organization (CRO) partner for clinical research than they were five years ago. That means business for many NC firms.

June 24

Premium Lock Triangle headlines: RTI-Zika research; Quintiles glucose monitoring; Cree's LED plant lights; PatientPay exec; Q2 award

Triangle headlines Triangle headline news this week includes: RTI to host Zika research; Quintiles offers new glucose monitoring service; Cree offers new LEDS to boost plants; PatientPay adds a new exec; and Quintiles joint venture Q2 wins an award.

June 21

Premium Lock Quintiles launches accelerator for healthcare apps development

Quintiles aims to speed up development for apps to boost healthcare with a new "Solution Design Studio." The accelerator's team will work with Quintiles clients in a variety of initiatives such as virtual reality and wearables.

Updated June 13

Premium Lock IMS merger could make Quintiles CEO $16.4M richer

Tom Pike  Tom Pike, chief executive officer of life science giant Quintiles, stands to make more than $16 million in cash and stock if Quintiles' merger with IMS Holdings wins shareholders' approval - and he stays with the company through 2017.

Updated June 8

Premium Lock Triangle headlines: NC in Fortune 500; TWC being 'bullied;' H-1Bs in Charlotte; Metabolon deal

Triangle headlines In our latest wrapup of Triangle headlines from other publications, catch up on reports about the new Fortune 500 and what North Carolina firms made it as well as news about Time Warner Cable, Metabolon and an investigation into H-1B visas in Charlotte.

June 3

Premium Lock Tech in brief: Quintiles enrollment; INC's new chair; CED venture pitches; Home Care Assist

Triangle technology briefs: Quintiles launches a precision enrollment program for oncology trials; INC Research's veteran cahir and former CEO retires, and a current board member takes over; the CED is looking for startups who want to pitch investors at its annual venture capital event; and a new home care screening service launches in Raleigh.

Updated May 24

Premium Lock 'Wow:' Quintiles takes vivid VR plunge to improve digital health

Darrell Pryor, news photographer for WRAL TV, utters a "wow" and smiles as he removes the virtual reality goggles during the first VR demo given by Quintiles to news media about its new VR initiative. But Quintiles isn't playing games. It's aiming to improve the clinical trials process and digital health. "We feel we are out there at the edge," says the Quintiles exec leading the VR charge. "People come out of the experience different." Indeed, they do.

May 20

Premium Lock Clinical trial of the future: How secondary data could add speed and accuracy to trial designs

On International Clinical Trials day, Cynthia Verst, the president of Clinical Operations at Quintiles, writes that the use of secondary data earlier in the research process can lead to "smarter, faster and more cost-sensitive clinical trials."

Cynthia Verst Cynthia Verst

Updated May 16

Premium Lock Profiling CED's first four Entrepreneur Hall of Famers

In announcing the first four selections for the new Entrepreneur Hall of Fame, the Council for Entrepreneurial development also provides succinct biographies. Here they are - with photos.

Dennis Gillings, center, rings in NYSE action Dennis Gillings, center, rings in NYSE action

Updated May 13

Premium Lock CED Entrepreneur Hall of Fame picks pioneers Dougherty, Gillings, Hutchison, Young

The Council for Entrepreneurial Development's new Hall of Fame is kicking off with a powerful lineup of honorees: The father of venture capital in North Carolina, the co-founder of Quintiles, a longtime tech industry lawyer, and the irrepressible co-founder of Red Hat.


Updated May 5

Premium Lock Countering downgrades, S&P gives Quintiles a post-merger boost

Quintiles            Three Wall Street firms have voted "no" on the big Quintiles-IMS Health merger so far by downgrading Quintiles stock. However, on Wednesday afternoon S&P Global Ratings weighed in with a positive review of the deal. WTW Insiders get the details.

Updated May 4

Premium Lock Quintiles, IMS to merge, forming $17.6B firm; Street lukewarm to deal

Durham-based life science services giant Quintiles is merging with IMS Health Holdings in a deal forming a company worth some $17.6 billion. The merger was announced early Tuesday. Quintiles founder Dennis Gillings will lead the combined board but IMS shareholders will hold majority of stock. Wall Street, however, reacts negatively to the news.

Quintiles' headquarters       Quintiles' headquarters

Updated May 4

Premium Lock CEOs' meeting leads to huge $17.6B Quintiles-IMS merger

The merger of Quintiles and IMS Health creating a $17 billion health services company announced Tuesday can be traced back to a meeting between the two CEOs last year. Quintiles' Tom Pike tells analysts the two firms discovered quickly how well they could work together, and the CEO of IMS says the collaboration has already delivered "major wins."

Tom Pike  Tom Pike

Updated May 3

Premium Lock Analyst: Q-IMS merger could trigger more deals; why Street doesn't like Q deal

Tech mergers Tuesday's merger of Quintiles with IMS Health Services might trigger other CRO deals affecting the Triangle, says Chapel Hill-based analyst Andrew Schafer of Industry Standard Research. Also, Wall Street is giving the Q deal the thumbs down as shares tumble 8 percent. Why? Schafer explains. Plus, a Bloomberg columnist weighs in.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith